Cancer Immunotherapy

Summary

The Cancer Virotherapy and Immunotherapy Group explores new anticancer treatments based on oncolytic adenoviruses and other immunotherapies. The group aims to design and evaluate oncolytic adenoviruses as antitumour agents for various solid tumours. The main lines of research are tumour targets, intratumoural diffusion through stromal barriers and oncolytic immunotherapy. The group also participates in other immunotherapy projects based on mutanome-derived cancer neoepitopes and cellular immunotherapy with modified NK cells.

243 Publications

Strategic lines

Research for oncolytic adenovirus tumour targets (Ramon Alemany)

Intratumoural diffusion of oncolytic adenoviruses through stromal barriers (Ramon Alemany)

Oncolytic immunotherapy (Ramon Alemany / Rafa Moreno)

Immunotherapy based on cancer neoepitopes (Ramon Alemany / Rafa Moreno / Josep Maria Piulats / Víctor Moreno)

Mesenchymal stem cells as carriers of oncolytic adenoviruses (Rafa Moreno)

Laboratory analysis associated with clinical trials with oncolytic adenoviruses (Rafa Moreno and Marcel Costa)

Selected Publications

Powles,T;Yuen,KC;Gillessen,S;Kadel EE,3RD; Rathkopf,D; Matsubara,N; Drake,CG et al, Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial., Nat. Med., 2022;28(1):144-153, doi:10.1038/s41591-021-01600-6,

Carvajal,RD;Butler,MO;Shoushtari,AN;Hassel,JC;Ikeguchi,A;Hernandez Aya,L;Nathan,P et al, Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial., Nat. Med., 2022;doi:10.1038/s41591-022-02015-7,

Marín Jiménez,JA;García Mulero,S;Matías Guiu,X;Piulats,JM, Facts and hopes in immunotherapy of endometrial cancer., Clin. Cancer Res., 2022;28(22):4849-4860, doi:10.1158/1078-0432.CCR-21-1564

Garcia Carbonero,R;Bazan Peregrino,M;Gil Martin,M; Alvarez,R;Macarulla,T; Riesco Martinez,MC;Verdaguer,H et al, Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors, J. Immunother. Cancer, 2022;10(3):doi:10.1136/jitc-2021-003255

Guix,I;Liu,Q;Pujana,MA;Ha,P;Piulats,J;Linares,I;Guedea,F et al, Validation of anti-correlated TGFß signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy., Clin. Cancer Res., 2022;28(7):1372-1382, doi:10.1158/1078-0432.CCR-21-2846

Selected Projects

20FIS039. Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM). Instituto de Salud Carlos III (ISCIII). Budget: 694346,29. 2020-2023. PI: Piulats Rodríguez, Josep María.

MCI21009. Inducción de muerte celular inmunogénica en tumores mediante el uso de adenovirus oncolíticos armados. Ministry of Science and Innovation (MICINN) Budget: 266200. 2021-2024. PI: Alemany Bonastre, Ramón.

FIS21131. RICORS TERAV. Instituto de Salud Carlos III (ISCIII). Budget: 170999,99. 2022-2024. PI: Alemany Bonastre, Ramón.

19ACL065. ESTUDIO DE FASE 2, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR EL TRATAMIENTO CON ACETATO DE ABIRATERONA MÁS PREDNISONA CON O SIN ABEMACICLIB EN PACIENTES CON CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN METASTÁSICO. Lilly S.A. Budget: 308260. 2019- . PI: Piulats Rodríguez, Josep María.

19ACL080. Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab (MK-3475) más docetaxel más prednisona frente a un placebo más docetaxel más prednisona en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) sin quimioterapia previa que han mostrado progresión con un fármaco hormonal de última generación (FHUG) (KEYNOTE-921). MERCK SHARP & DOHME ESPAÑA S.A. Budget: 262983. 2019- . PI: Piulats Rodríguez, Josep María.

Technology transfer